Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Moody's
MCO
5
Apple
AAPL
CN Stock MarketDetailed Quotes
002898 Sailong Pharmaceutical Group
- 6.26
- +0.29+4.86%
Market Closed Apr 30 15:00 CST
1.10BMarket Cap-30.84P/E (TTM)
6.27High5.93Low99.44KlotVolume5.93Open5.97Pre Close61.04MTurnover9.82%Turnover RatioLossP/E (Static)176.00MShares12.3952wk High2.21P/B633.90MFloat Cap5.7752wk Low6.27Limit Up101.26MShs Float30.73Historical High5.67Limit Down5.70%Amplitude5.77Historical Low0.02Dividend TTM6.14Avg Price48.55KlotAsk0.32%Div YieldTTM100Lot Size50.03KlotBid
Sailong Pharmaceutical Group News
*ST Ceylon: Announcement on the subsidiary obtaining a registration certificate for injectable voriconazole
Sailong Pharmaceutical: Announcement on the receipt of a warning letter from the Guangdong Securities Regulatory Bureau by the Company and related personnel
Sailong Pharmaceutical: Special instructions on the proposed non-distribution of profits in 2024
Sailong Pharmaceutical: 2024 Independent Director Debriefing Report (Chen Xiaoxin)
Cailong Pharmaceutical: Announcement of Supervisory Board Resolutions
Cailong Pharmaceutical: Internal Control Self-Assessment Report
Cailong Pharmaceuticals: Internal Control Audit Report
Cailong Pharmaceutical: Notice of Annual General Meeting of Shareholders
Cailong Pharmaceuticals: 2024 Annual Audit Report
Cailong Pharmaceutical: Report on the work of the Supervisory Committee in 2024
Sailong Pharmaceutical: 2024 Financial Results Report
Sailong Pharmaceutical: Announcement on Delisting Risk Warning and Suspension of the Company\'s Stock Trading
Sailong Pharmaceutical: Explanation of the Board of Directors and Audit Committee on the reasonableness of the company\'s impairment preparations
Sailong Pharmaceutical: 2024 Independent Director Debriefing Report (Li Gongfen)
Sailong Pharmaceutical: Announcement on 2024 Asset Impairment Preparation
Cailong Pharmaceutical: Announcement of Board Resolutions
Cailong Pharmaceuticals: First Quarter Report 2025
Sailong Pharmaceutical: Review Opinions of the Fourth Board of Directors Audit Committee Meeting at its 2nd Meeting in 2025
Sailong Pharmaceutical: Report on the 2024 Performance Evaluation of Accounting Firms and the Audit Committee\'s Performance of Supervisory Duties
Sailong Pharmaceutical: Explanation of the Supervisory Board on the reasonableness of the company\'s impairment preparations
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts